Forte Biosciences (FBRX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	16.36 mm	16.36 mm	16.36 mm	16.36 mm	16.36 mm	16.36 mm
Cash burn (monthly)	2.71 mm	2.49 mm	2.88 mm	2.97 mm	2.71 mm	2.48 mm
Cash used (since last report)	13.78 mm	12.63 mm	14.61 mm	15.09 mm	13.77 mm	12.58 mm
Cash remaining	2.58 mm	3.74 mm	1.75 mm	1.28 mm	2.59 mm	3.79 mm
Runway (months of cash)	1.0	1.5	0.6	0.4	1.0	1.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

FBRX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	32	42	-23.8%
Opened positions	3	4	-25.0%
Closed positions	13	3	+333.3%
Increased positions	0	6	EXIT
Reduced positions	21	7	+200.0%

13F shares	Current	Prev Q	Change
Total value	4.13 bn	10.29 bn	-59.8%
Total shares	16.26 mm	36.35 mm	-55.3%
Total puts	0.00	0.00
Total calls	0.00	3.10 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Farallon Capital Partners	3.49 mm	$0.00	0.0%
Biotechnology Value Fund L P	2.98 mm	$3.01 mm	0.0%
Funicular Funds	2.03 mm	$0.00	0.0%
BML Investment Partners	1.76 mm	$1.41 mm	0.0%
Camac Fund	1.46 mm	$819.00 k	0.0%
ATG Fund II	1.46 mm	$1.81 mm	0.0%
JEC II Associates	1.14 mm	$1.16 mm	0.0%
Funicular Fund	1.11 mm	$1.45 mm	0.0%
Tybourne Capital Management	144.98 k	$810.44 mm	-96.0%
BVF	119.28 k	$667.98 mm	-96.0%

Largest transactions	Shares	Bought/sold	Change
Tybourne Capital Management	144.98 k	-3.48 mm	-96.0%
Perceptive Advisors	95.74 k	-3.17 mm	-97.1%
BVF	119.28 k	-2.86 mm	-96.0%
Cable Car Capital	81.28 k	-1.95 mm	-96.0%
Fred Alger Management	82.70 k	-1.76 mm	-95.5%
Alger Associates	82.70 k	-1.76 mm	-95.5%
Farallon Capital Management	72.41 k	-1.74 mm	-96.0%
BML Capital Management	70.47 k	-1.69 mm	-96.0%
Vanguard	26.39 k	-638.84 k	-96.0%
Geode Capital Management	14.27 k	-332.02 k	-95.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

FBRX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jan 25	Wagner Paul A.	Common Stock	Payment of exercise	Dispose F	No	No	22.71	164	3.72 k	78,556
1 Jan 25	Wagner Paul A.	Common Stock	Option exercise	Acquire M	No	No	0	1,250	0.00	78,720
1 Jan 25	Wagner Paul A.	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,250	0.00	10,000
1 Jan 25	Riley Antony A	Common Stock	Payment of exercise	Dispose F	No	No	22.71	154	3.50 k	30,997
1 Jan 25	Riley Antony A	Common Stock	Option exercise	Acquire M	No	No	0	375	0.00	31,151
1 Jan 25	Riley Antony A	RSU Common Stock	Option exercise	Dispose M	No	No	0	375	0.00	3,000
21 Nov 24	Riley Antony A	Common Stock	Buy	Acquire P	No	No	5.552	22,514	125.00 k	30,776
1 Oct 24	Wagner Paul A.	Common Stock	Payment of exercise	Dispose F	No	No	5.16	98	505.68	77,470
1 Oct 24	Wagner Paul A.	Common Stock	Option exercise	Acquire M	No	No	0	1,250	0.00	77,568
1 Oct 24	Wagner Paul A.	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,250	0.00	11,250

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

TD Cowen Initiates Coverage On Forte Biosciences with Buy Rating

21 Jan 25

TD Cowen analyst Yaron Werber initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating.

Why Forte Biosciences (FBRX) Stock Is Trading Lower

16 Dec 24

Forte Biosciences shares are trading lower by 13.6% Monday afternoon. The company announced plans for the periodic resale of up to 9.5 million common stock shares by selling stockholders.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

4 Dec 24

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $64 Price Target

4 Dec 24